PAR

Par Drugs And Chemicals Limited

Source: NSE · Updated 4 Nov, 11:32 pm IST

Filed 29 Oct, 05:21 pm IST Q2 FY27 (Sep ’26)Standalone (no consolidated filing)₹ lakhs

Revenue

2,743.19

▼ 4.3% vs Q2 FY26

Operating profit (EBITDA, derived from filing)

450.28

▼ 25.8% vs Q2 FY26

Net profit

262.8

▼ 36.4% vs Q2 FY26

EPS (₹)

2.14

▼ 36.3% vs Q2 FY26

Operating margin

16.4%

−480 bps vs Q2 FY26

Net margin

9.6%

−480 bps vs Q2 FY26

Revenue down, profit down vs Q2 FY26

Revenue−4% vs Q2 FY26 · −12% vs Q1 FY27

Profit−36% vs Q2 FY26 · −44% vs Q1 FY27

View official filing ↗

Numbers from the company's structured XBRL filing on NSE, cross-checked with P&L totals.

Previous-quarter and year-ago figures: as originally reported in those quarters' NSE filings; filing PDF not available to confirm restatements.

Quarter comparison

Item	Q2 FY27 (Sep ’26)	Q1 FY27 (Jun ’26)	vs Q1 FY27	Q2 FY26 (Sep ’25)	vs Q2 FY26
Revenue from operations	2,743.19	3,128.05	▼ 12.3%	2,865.89	▼ 4.3%
Other income	0.08	93.53	▼ 99.9%	48.01	▼ 99.8%
Total income	2,743.27	3,221.58	▼ 14.8%	2,913.9	▼ 5.9%
Total expenses	2,388.91	2,588.57	▼ 7.7%	2,358.88	▲ 1.3%
Operating profit (EBITDA)*	450.28	638.04	▼ 29.4%	606.61	▼ 25.8%
Profit before tax	354.36	633.01	▼ 44.0%	555.02	▼ 36.2%
Tax expense	91.56	161.74	▼ 43.4%	142.06	▼ 35.5%
Net profit	262.8	471.27	▼ 44.2%	412.96	▼ 36.4%
EPS (₹)	2.14	3.83	▼ 44.1%	3.36	▼ 36.3%
Operating margin	16.4%	20.4%	−400 bps	21.2%	−480 bps
Net margin	9.6%	15.1%	−550 bps	14.4%	−480 bps

Showing Q2 FY27 (Sep ’26) and change vs Q2 FY26. Turn your phone sideways for Q1 FY27 (Jun ’26).

Figures in ₹ lakhs except EPS. Standalone figures from the company's XBRL filing on NSE. Each row is shown only if it reconciles with the others (e.g. PBT − tax = net profit); rows we couldn't verify are left out. Net margin = net profit ÷ revenue. *Operating profit (EBITDA), derived from the filing: profit before exceptional items and tax + finance costs + depreciation − other income. Operating margin = EBITDA ÷ revenue.

All Par Drugs And Chemicals results, dividends & filings ›

Other results filed 29 Oct

ACI Archean Chemical Industries Limited›KALPATARU Kalpataru Limited›SUDARSHAN Sudarshan Pharma Industries Limited›STLNETWORK STL Networks Limited›LAURUSLABS Laurus Labs Limited›SURYODAY Suryoday Small Finance Bank Limited›ARCIL Asset Reconstruction Company (India) Limited›RBA Restaurant Brands Asia Limited›ASIANPAINT Asian Paints Limited›MONARCH Monarch Networth Capital Limited›CARERATING CARE Ratings Limited›AYMSYNTEX AYM Syntex Limited›

Today's results ›

PAR DRUGS AND CHEMICALS Q2 FY27 ; NET PROFIT DOWN 36% AT ₹2.63 CR (YOY), DOWN 44% (QOQ)

REVENUE DOWN 4% AT ₹27 CR (YOY), DOWN 12% (QOQ)

EBITDA DOWN 26% AT ₹4.50 CR (YOY), DOWN 29% (QOQ)

MARGINS AT 16.4% VS 21.2% (YOY), 20.4% (QOQ)

https://resultkal.com/r/par-2026-10-29
Source: NSE filing · not investment advice

FAQ

When did Par Drugs And Chemicals announce Q2 FY27 results?

Par Drugs And Chemicals filed its results on NSE on 29 Oct, 05:21 pm IST.

What does QoQ and YoY mean?

QoQ compares with the previous quarter; YoY compares with the same quarter last year. Growth is calculated from the figures in the filing.

Are these Par Drugs And Chemicals figures official?

They are auto-read from the company's NSE filing and may contain errors. Always confirm with the official PDF linked on this page.

Explore

Today's results Results this week Q2 FY27 results dates Dividend stocks this week Bonus issue 2026 Stock split 2026

Figures are auto-read from the company's NSE filing and may contain errors. Check the official filing before deciding. Not investment advice.

← PAR overview